LinkOPH

Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a joint society of cornea, cataract and refractive surgery specialists, here to discuss some of the latest hot topics in ophthalmology.Dry eye disease is one of the most frequently seen problems in the eye care professional’s office. Cyclosporine drops have become the mainstay of treatment of this condition. Some physicians have noted difficulty with the initiation of cyclosporine due to the delay in onset and the subjective irritation some patients note upon instillation. This month, Jonathan D. Solomon, MD, and Cynthia A. Matossian, MD, FACS, discuss their strategies to initiate cyclosporine with their patients. We hope you enjoy this discussion.

Read more →

Three emerging forms of laser trabeculoplasty compare well with established modalities in terms of safety and efficacy, according to a published report.Argon laser trabeculoplasty was the preferred form of laser trabeculoplasty for more than 4 decades,…

Read more →

The Hoopes family has been involved in refractive surgery from the early days of RK to the current, most advanced vision correction procedures of LASIK and ICLs. Phil Sr. and Phil Jr. not only talk the talk, but they walk the walk.Phil Jr.’s myopia progressed after his early RK procedure. Although some surgeons are reluctant to perform LASIK over previous RK, many of us have had excellent results. Phil Jr. is a great example of this.

Read more →

The eye care market is expected to comprise 10% of Valeant Pharmaceuticals International’s business in 2016, Howard Schiller, the company’s then interim CEO, reported at the 2016 J.P. Morgan Healthcare Conference, with overall U.S. revenues expected to total $12.5 billion to $12.7 billion.“In U.S. ophthalmology, since we bought B+L, we’ve taken our contact lens market share from 6% to almost 10%. In a tough cataract surgery market, we gained share against tough competition. Once we get the glaucoma approval later this year, we’ll have another engine for growth,” Schiller said, referring to the FDA review of Vesneo (latanoprostene bunod), a once-daily IOP-lowering single-agent eye drop for patients with open-angle glaucoma or ocular hypertension.

Read more →

A 31-year-old man presented from an outside hospital with a 3-month history of headaches and 6 days of blurry vision in both eyes. He was previously found to have a dural venous sinus thrombosis on CT and MRI. He described the decline in vision to be “fairly sudden” and “a black cloud” in the center of his vision, greater in the right eye than the left eye. He was transferred to our hospital for complete work-up of his dural venous sinus thrombosis and acute decline in vision.His ocular history was unremarkable. His medical history was significant for an unprovoked deep venous thrombosis 3 years prior, as well as multiple episodes of oral and genital ulcers. He had not had any prior surgeries, and his family history was unremarkable. He was born in the Dominican Republic. He denied tobacco, alcohol or illicit drug use as well as risk-taking sexual activity. He denied any known drug allergies.

Read more →